MedTrace Logo

Developing a Comprehensive Biomarker Panel for Monitoring Progression and Early Detection in ALS Patients

NCT07737977 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2026-07-30

No results posted yet for this study

Summary

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease for which reliable biomarkers for early diagnosis, prognosis, and patient stratification remain limited. Previous genetic, proteomic, imaging, and electrophysiological studies have identified potential biomarkers and phenotype modifiers, improving the understanding of motor neuron degeneration mechanisms. However, these findings have not yet been translated into a clinically useful biomarker algorithm. This observational study aims to develop a biomarker panel to support the diagnosis, prognosis, and stratification of patients with ALS. Clinical and molecular biomarkers previously associated with ALS phenotypes will be analyzed simultaneously and integrated into a multivariable predictive model. Clinical data and biological samples will be collected and analyzed to identify combinations of biomarkers associated with ALS phenotypes.

Conditions

  • ALS (Amyotrophic Lateral Sclerosis)

Interventions

OTHER

peripheral venous blood collection

collection of an additional 24 mL of blood following a routine blood draw

OTHER

collection of medical data related to patient care

collection of medical data from patient care during the 12-month follow-up period, drawn from electronic medical records, including laboratory test results, clinical examination findings, and paraclinical test results

Sponsors & Collaborators

  • Hospital Universitari Vall d'Hebron Research Institute

    collaborator OTHER

  • University Hospital, Montpellier

    lead OTHER

Principal Investigators

  • Florence ESSELIN, MD · University Hospital, Montpellier

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-31
Primary Completion
2029-02-28
Completion
2029-08-31

Countries

  • France
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07737977 on ClinicalTrials.gov